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SUMMARY 
For the contract period 1966-1967 it was proposed to concentrate on 
methods aimed at the selection of bone marrow donors with maximum 
histocompatibility with regard to the irradiated recipients. 
Most of the work carried out during 1966 has been on the typing of 
leucocyte antigens, as is currently being pursued in man. 
A major advance in the control of secondary disease was achieved by 
the introduction of anti-lymphocyte serum to treat the bone marrow 
recipients after the transplantation. 
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INVESTIGATIONS ON BONE MARROW TRANSPLANTATION 
IN IRRADIATED ANIMALS (+) 
INTRODUCTORY NOTE 
For the contract period 1966 - 1967 it was proposed to concentrate 
on methods aimed at the selection of bone marrow donors with maximum 
histocompatibility with regard to the irradiated recipiento. In the pre-
ceding years the suppression of acute secondary disease had been effective-
ly achieved by the early administration of certain chemotherapeutic agents, 
but this treatment was not sufficient to cause long lasting control of second-
ary disease and stable chimaerism, It was envisaged that a reduction of the 
degree of histoincompatibility between the donors and the recipients would 
allow further improvements of the condition of the bone marrow chimaeras. 
These methods of selection are obviously of similar importance for the 
field of organ transplantation and the study in monkeys would facilitate 
extrapolation of the results to man. 
The main approach to the problem of selection is the typing of lcuco-
cyte antigens, as is currently being pursued in man. Most of the work 
carried out during 1966 has been on this subject. In addition experiments 
have been carried out with the so called "third man te6t 11 , which is based 
(+)Manuscript received on April 4, 1968. 
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on the sensitization of a third party with skin grafts of the recipient, follow-
ed by grafting of skin from a number of prospective donors. 
Further control of secondary disease was attempted by the use of two 
new methods. The first - protection of the host by specific antiscra -
was not reproducibly successful. The second - treatment with hetcrologous 
anti-monkey lymphocyte sera - was strikingly effective but the side-effects 
caused by this treatment, were found to constitute a major obstacle. 
A considerable amount of preliminary and fundamental work was per-
formed on the effects of anti lymphocyte sera in mice, using a model 
which initiates acute secondary disease as it occurs in monkeys and man 
following grafting of homologous bone marrow. 
Using rodent tissues a quantitative technique for the determination 
of immune competent cells was employed to study the kinetics of the 
population of immunologically active cells in an attempt to collect more in-
formation on the development of the graft versus host reaction and of im-
munological tolerance. With this technique the radiosensitivity of the im-
mune response and the speed of recovery after irradiation can be quanti-
tatively determined. 
Histocompatibility testing in Rhesus monkeys 
a. Studies on the applicability of the third man test, 
The third man test is a comparatively simple method to detect similar-
ities in the transplantation antigen make up between individuals, It has been 
employed by Mathe for the selection of relatively compatible donors in 
human bone marrow transplantation. It was found that the test can also be 
easily performed in monkcyo by grafting pieces of skin on the back, A 
monkey receives a skin graft from another monkey (first party or bone 
marrow recipient). After the graft has been rejected, skin grafts from a 
number of other individuals (second parties or potential bone marrow donors 
A, B, C) are made on the same individual (third party). The rejection 
pattern of the grafts A, B and C is determined by antigenic similarities 
between these and the recipient, in other words, the graft that is rejected 
most rapidly is from a donor that is probably the most similar to the first 
party (recipient). Only similarities, not differences, are detected by this 
technique. Also, the results of the test arc stron3ly influenced by the im-
munogcnetic composition of the third party. 
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Several bone marrow transplantation experiments were performed 
with donors and recipients selected for maximal and minimal histo-
compatibility. The degree of secondary disease which developed was 
not well correlated with the results of the third man test, which is 
probably due to the failure of the test to detect differences between 
individuals (1). The method was therefore abandoned. In a separate 
study using both M. rhesus and M. speciosa monkeys, it was shown that 
similar information can be obtained by a much simpler serological 
procedure based on the recognition of leucocyte antigens by multi-
specific iso-antisera in vitro. Some representative results are shown 
in Table I. 
On the basis of these results a selection method for clinical use 
has been prepared (4) which io performed as follows. A patch of skin 
from the patient would be placed on a third party volunteer and this 
should preferably be followed by one or two lcucocyte injections intra-
dermally, to obtain a stronger serum. This serum would be the reagent 
in a cytotoxicity test on the leucocytes of potential donors. The leuco-
cytes reacting strongly with the serum would be the ones having some 
strong transplantation antigens in common with the patient. The most 
eligible of such preselected donors should preferably be further screen-
ed by other histocompatibility tests - including, if desired and feasible, 
the actual grafting of skin on the same previously immunized third party. 
b. Leucocyte antigen typing. 
In collaboration with the Department of Immuno-haematology at Leyden 
"mono-specific" serological reagents have been produced by iso-immuni-
sation and absorbtions, guided by the results of computer analyses of 
serum reactivit;es (11). 
In this way sera were obtained which recognize two probably allelic 
leucocyte antigenic complexes, the composition of which is under further 
investigation. The importance of these two antigens (named la and lb) for 
histocompatibility was demonstrated with skin grafting experiments. This 
became possible by the availability of anti-lymphocyte-serum which has 
a powerful immunosuppressing activity. Such immunosuppression is re-
quired to cause a sufficient spread of the range of skin graft rejection 
- 8 -
Table I 
COMPARISON OF SERUM CYTOTOXICITY AGAINST 
LEUCOCYTES AND HOMOGRAFT REJECTION-TIMES 
IN PREVIOUSLY IMMUNIZED MACACA SPECI03A 
Third party 
(previously 
immunized) 
Third party serum cytotoxicity 
against leucocytes 
Type % toxicity 
. Sk_in gr.aft :z 
reJect1on-time 
(days) 
-k 
1 55 6 
2 10 8 
A 3 10 10 
4 10 10 
5 10 10 
1 5 10 
2 10 9 
B 3 90 5 
4 15 8 
5 50 5 
1 10 10 
2 100 5 
C 3 60 6 
4 5 10 
5 15 10 
1 10 10 
2 10 10 
D 3 100 7 
4 5 9 
5 100 5 
Skin grafts from same donor as leucocyte sample tested. Previous 
immuni.zation was done by one skin graft followe1, 2 weeks later by a 
subcutaneous or intravenous injection of 200 x l O leucocytes; 
third party reactivity against this donor is not included in table. Graft 
rejection is accelerated if it occurs before day 8 
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times to allow a distinction between compatible and incompatible 
donors. 
Preliminary experiments, using ALS in monkeys, showed that 
incompatibility for either antigen la or lb sie;nificantly reduced the 
survival time of a skin graft. This refinement of tissue typing in 
Rhesus monkeys may obviously be of major importance for success-
ful transplantation of homologous bone marrow and of organ trans-
plantation. Data are being collected to establioh the significance c£ 
compatibility for leucocyte groups la and lb for the severity of second-
ary disease in irradiated monkeys. 
In addition the technique of kidney transplantation in the Rhesus 
monkey is being developed in collaboration with the Surgical Department 
at Leyden to permit the future evaluation of the significance of the pre-
sently identified lcucocyte antigen groups for the selection of suitable 
kidney donors. 
The identification of antigens la and lb also facilitates the detection 
of further major leucocytc and transplantation antigens. Host/ donor 
combinations for immunisations are now being selected to yield anti-
s era not directed against antigens Ia and lb, These sera are likely to 
lead to the seroloeical identification of new major antigens within the 
near future. Obviously, recognition of new, defined, antigens n1akes 
host/donor matching according to leucocyte antigens more meaningful. 
Suppression and prevention of secondary disease 
in primates 
Following the renewed interest in the use of anti lymphocyte sera 
(ALS) to facilitate homotransplantation it was decided to investigate the 
possibilities of ALS to prevent or nuppress secondary disease following 
homologous bone marrow transplantation. For this purpose an extensive 
program in mice was initiated. At the Game time the production of anti-
monkey lymphocyte sera and the evaluation of their capacity to prolong 
skin homografts was started. It Goon became apparent that ALS is a 
mo::;t powerful agent in counteracting acute secondary disease in n'1ice. 
It was found to be most effective when employed to pretreat the spleen 
donors but a selective inhibition of the graft verous host reaction could 
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also be obtained by exposing the spleen cells in vitro to ALS prior 
to grafting and by treating the recipients after the transplantation 
of homologous spleen cells. So far these experiments were perform-
ed with rabbit anti-mouse lymphocyte serum, but large batches of 
horse anti-mouse lymphocyte serum have now also be produced for 
isolation of the active 'I globulin, which will be used in further 
studies. 
In the initial part of the studies in Rhesus monkeys, Cynomolcus 
and Rhesus anti-lymphocyte sera were produced, later to be sub-
stituted by rabbit and horse sera. The latter were much more effect-
ive in prolonging the survival of a homograft, 
With crude rabbit ALS a treatment regimen has been worked out 
which allows virtually permanent survival of skin homografts, without 
causing clinical signs of toxicity of the ALS. These results justify the 
conclusion that ALS is the most powerful immunosuppressive agent 
so far developed. Its application in experimental and clinical organ 
transplantation is now well under way in a number of centers, including 
the Rijswijk-Leyden group. 
Application to the problem of secondary disease in monkeys has 
also yielded most encouraging results. By the administration of large 
doses of ALS to the irradiated bone marrow recipient after the graft-
ing it proved possible 
1. to prevent the acute phase of secondary disease as effectively as 
can be achieved by the early administration of cyclophosphamide 
2, to prevent the later phase of secondary disease to a large extent. 
Unfortunately monkeys thus treated have succumbed from wide 
spread virus infections, identified as the cytomegaly virus. 
3. to control and reverse acute secondary disease after it has become 
clinically manifest. 
These results are summarized in Table II. 
Some of these results have been published (11), and a report 
containing the main data of this investigation is in press (7), 
It seems therefore that a meth8d has been described to treat second-
ary disease effectively. In monkt..:!ys at least, the degree of immunosup-
Table II 
RESULTS OF TREATMENT OF ACUTE AND DELAYED SECONDARY 
DISEASE IN MONKEYS WITH ALS 
Monkey ALS Survival Secondary 
l st day nr. dose ml/day time days disease 
monkey 643 13 5 ) 400 
-
ALS i. v. 727 10 5 21 severe 
Early cyclo, 712 13 2 - 5 23 moderate 
followed rabbit- 792 16 4 - 6 24 severe 
byALS ALS s. c. 704 13 5 - 10 33 slight 
798 14 5 - 20 40 alight 
753 11 10 - 20 33 slight 
No cyclo, rabbit- 781 2 2 - 10 39 moderate 
ALS only AL3 s. c. 805 2 5 - 15 33 sliiht 
Compl. 
} phlebitis -and -
edema 
virus 
virus 
virus 
virus 
virus 
virus 
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pression necessary to achieve this causes the recipients to fall victim 
to a fatal virus infection. It can only be established by future invest-
igations if and how this complication can be avoided. Obviously it is 
not known for certain whether a similar susceptibility to endogenous 
virus infections will occur in humans as a result of intensive treat-
ment with ALS, but on the basis of close similarity in response 
-between monkeys and man, it should be considered an extremely 
serious hazard. 
The in vitro effect of anti-monkey LG on monkey bone marrow 
suspensions wafl disappointing, in that the selectivity of its action was 
insufficient for practical purposes. It was not possible to obtain re-
producible elimination of the immunologically active cells with con-
committent preservation of the hemopoietic cells in the suspension. 
This approach was therefore abandoned. 
Prior treatment of the donor with doses of ALS which were capable 
of prolonging homograft survival were completely ineffective in de-
creasing the severity of the acute secondary disease. However, for 
the results e,btained in mice it might be concluded that these doses of 
ALS have been too small. Additional experiments with higher doses of 
ALS are therefore envisaged. 
Furthermore, an effective horse anti-monkey LS has been produced 
which will be used to produce a purified 'I globulin for further invest-
igations concerning the suppression of secondary disease and to study 
the occurrence of pathological effects of the prolonged treatment with 
ALS in monkeys. 
Investigations on the quantitative determination of immune 
competent cells in rodent tissues 
The comparative study on "cluster" and "plaque" formation by anti-
body forming cells in vitro has been completed. A publication entitled: 
"Antibody production by isolated spleen cells; a study on the cluster and 
plaque technique" is in preparation. From these investigations the 
following conclusions could be drawn: 
1. Cells producing 19 s antibodies against sheep red blood cells will 
form clusters when incubated in a suspension together with sheep RBC. 
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Plaques are formed when these cells are embedded in agar and 
complement is added. 
2. Cells producing 7 s antibodies against sheep RBC also form clusters 
when incubated in suspension with sheep RBC. Plaque formation in 
agar will however occur only when an anti-mouse globulin serum is 
added with the complement (indirect plaque test). 
3. A large portion of the antibody forming cells produce insufficient 
antibody molecules to cause visible plaque formation. These cells 
can still be discerned with the more sensitive cluster technique. 
4. About 40 per cent of the total number of cluster forming cells do not 
excrete antibodies although they will fix the antigen (sheep RBC) on 
their cell surface, 
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